Randolph D Andrews
Overview
Explore the profile of Randolph D Andrews including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
13
Citations
312
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Matthews D, Kinney J, Ritter A, Andrews R, Toledano Strom E, Lukic A, et al.
Alzheimers Dement (N Y)
. 2024 Jul;
10(3):e12490.
PMID: 38988416
Introduction: The "A/T/N" (amyloid/tau/neurodegeneration) framework provides a biological basis for Alzheimer's disease (AD) diagnosis and can encompass additional changes such as inflammation ("I"). A spectrum of T/N/I imaging and plasma...
2.
Shuping J, Matthews D, Adamczuk K, Scott D, Rowe C, Kreisl W, et al.
Alzheimers Dement (N Y)
. 2023 Mar;
9(1):e12372.
PMID: 36873926
Background: The positron emission tomography (PET) radiotracer [F]MK-6240 exhibits high specificity for neurofibrillary tangles (NFTs) of tau protein in Alzheimer's disease (AD), high sensitivity to medial temporal and neocortical NFTs,...
3.
Matthews D, Lukic A, Andrews R, Wernick M, Strother S, Schmidt M
Alzheimers Dement (N Y)
. 2022 Jul;
8(1):e12325.
PMID: 35846158
Introduction: Amyloid measurement provides important confirmation of pathology for Alzheimer's disease (AD) clinical trials. However, many amyloid positive (Am+) early-stage subjects do not worsen clinically during a clinical trial, and...
4.
Matthews D, Mao X, Dowd K, Tsakanikas D, Jiang C, Meuser C, et al.
Brain
. 2021 Jun;
144(12):3742-3755.
PMID: 34145880
Dysregulation of glutamatergic neural circuits has been implicated in a cycle of toxicity, believed among the neurobiological underpinning of Alzheimer's disease. Previously, we reported preclinical evidence that the glutamate modulator...
5.
Matthews D, Ritter A, Thomas R, Andrews R, Lukic A, Revta C, et al.
Alzheimers Dement (N Y)
. 2021 Feb;
7(1):e12106.
PMID: 33614888
Background: A Phase II proof of concept (POC) randomized clinical trial was conducted to evaluate the effects of rasagiline, a monoamine oxidase B (MAO-B) inhibitor approved for Parkinson disease, in...
6.
Walters M, Sterling J, Quinn C, Ganzer C, Osorio R, Andrews R, et al.
BMJ Open
. 2018 Nov;
8(11):e023664.
PMID: 30478117
Objective: To investigate the associations between lifestyle and vascular risk factors and changes in Alzheimer's disease (AD) biomarkers (beta-amyloid load via C-PiB PET, glucose metabolism via F-FDG PET and neurodegeneration...
7.
Matthews D, Lerman H, Lukic A, Andrews R, Mirelman A, Wernick M, et al.
Neuroimage Clin
. 2018 Sep;
20:572-579.
PMID: 30186761
Background: The development of therapeutic interventions for Parkinson disease (PD) is challenged by disease complexity and subjectivity of symptom evaluation. A Parkinson's Disease Related Pattern (PDRP) of glucose metabolism via...
8.
Rafii M, Lukic A, Andrews R, Brewer J, Rissman R, Strother S, et al.
J Alzheimers Dis
. 2017 Sep;
60(2):439-450.
PMID: 28946567
Background: Adults with Down syndrome (DS) represent an enriched population for the development of Alzheimer's disease (AD), which could aid the study of therapeutic interventions, and in turn, could benefit...
9.
Matthews D, Lukic A, Andrews R, Marendic B, Brewer J, Rissman R, et al.
Alzheimers Dement (N Y)
. 2017 Jun;
2(2):69-81.
PMID: 28642933
Introduction: Down Syndrome (DS) adults experience accumulation of Alzheimer's disease (AD)-like amyloid plaques and tangles and a high incidence of dementia and could provide an enriched population to study AD-targeted...
10.
Matthews D, Davies M, Murray J, Williams S, Tsui W, Li Y, et al.
Adv J Mol Imaging
. 2015 Jan;
4(4):43-57.
PMID: 25599008
Methods: Forty-five NL individuals (age 54 ± 11, 71% women) with complete leisure time physical activity (LTA), dietary information, and cross-sectional 3D T1-weigthed MRI, C-Pittsburgh Compound B (PiB) and F-fluorodeoxyglucose...